Syngene shares jump 17% after Q4 results; check Macquarie price target

Shares of Syngene International Ltd. surged as much as 17% on Thursday, April 30, after the company reported its Q4FY26 earnings.Revenue for the quarter rose 1.8% year-on-year to ₹1,037 crore from ₹1,018 crore. However, profitability remained under pressure, with net profit declining 19.3% YoY to ₹147.9 crore.

EBITDA fell 11.7% to ₹303.4 crore from ₹343.6 crore in the year-ago period, leading to a sharp 450 basis points contraction in EBITDA margin to 29.3%.
Brokerage firm Macquarie has maintained an ‘Outperform’ rating on the stock, with a price target of ₹835 per share.The brokerage said that EBITDA was 11% ahead of its estimates on in-line revenue, while adjusted PAT of ₹150 crore came in 8% below expectations.

Reported net profit included a ₹20 crore gain related to the remeasurement of gratuity obligations, which was more than offset by a ₹25 crore charge linked to employee termination benefits.

The company said that revenue continues to be impacted by lower business from a single large molecule biologics client. Excluding this, the underlying business showed steady momentum.